GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (OTCPK:ROQAF) » Definitions » Quick Ratio

ROQAF (Roquefort Therapeutics) Quick Ratio : 0.79 (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Roquefort Therapeutics Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Roquefort Therapeutics's quick ratio for the quarter that ended in Jun. 2024 was 0.79.

Roquefort Therapeutics has a quick ratio of 0.79. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Roquefort Therapeutics's Quick Ratio or its related term are showing as below:

ROQAF' s Quick Ratio Range Over the Past 10 Years
Min: 0.79   Med: 3.9   Max: 63.86
Current: 0.79

During the past 3 years, Roquefort Therapeutics's highest Quick Ratio was 63.86. The lowest was 0.79. And the median was 3.90.

ROQAF's Quick Ratio is ranked worse than
83.37% of 1503 companies
in the Biotechnology industry
Industry Median: 3.41 vs ROQAF: 0.79

Roquefort Therapeutics Quick Ratio Historical Data

The historical data trend for Roquefort Therapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Quick Ratio Chart

Roquefort Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Quick Ratio
15.69 8.66 2.26

Roquefort Therapeutics Semi-Annual Data
Jun21 Jun22 Dec22 Jun23 Dec23 Jun24
Quick Ratio Get a 7-Day Free Trial 3.13 8.66 4.66 2.26 0.79

Competitive Comparison of Roquefort Therapeutics's Quick Ratio

For the Biotechnology subindustry, Roquefort Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roquefort Therapeutics's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roquefort Therapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Roquefort Therapeutics's Quick Ratio falls into.



Roquefort Therapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Roquefort Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.88-0)/0.389
=2.26

Roquefort Therapeutics's Quick Ratio for the quarter that ended in Jun. 2024 is calculated as

Quick Ratio (Q: Jun. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.869-0)/1.098
=0.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Roquefort Therapeutics  (OTCPK:ROQAF) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Roquefort Therapeutics Quick Ratio Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Roquefort Therapeutics Business Description

Traded in Other Exchanges
Address
85 Great Portland Street, First Floor, London, GBR, W1W 7LT
Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. Its product portfolio consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical next-generation medicines focused on hard-to-treat cancers.

Roquefort Therapeutics Headlines